静脈注射用鉄剤の世界市場2017-2021...市場調査レポートについてご紹介

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: An overview of iron deficiency

PART 06: Pipeline landscape

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by product type
• Ferric carboxymaltose
• Sucrose
• Dextran
• Others

PART 09: Geographical segmentation
• Intravenous iron drugs market in Americas
• Intravenous iron drugs market in EMEA
• Intravenous iron drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 12: Market trends
• Increase in favorable guidelines from healthcare organizations
• Increasing strategies of vendors to expand reach of intravenous iron drugs
• Growing focus on emerging economies

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Allergan
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos
• Other prominent vendors

PART 15: Appendix
• List of abbreviation

[List of Exhibits]

Exhibit 01: Pipeline landscape
Exhibit 02: Global intravenous iron drugs market
Exhibit 03: Annual shipment sales growth of Ferinject/Injectafer in key countries in 2015
Exhibit 04: Global intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 05: Global intravenous iron drugs market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by product type 2016
Exhibit 08: Ferric carboxymaltose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 09: Global sucrose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 10: Global dextran-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 11: Global other intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 12: Global intravenous iron drugs market by geography 2016 and 2021
Exhibit 13: Global intravenous iron drugs market by geography: Revenue 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Intravenous iron drugs market in the Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Intravenous iron drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Intravenous iron drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Impact of drivers
Exhibit 21: Cost comparison of key drugs per week 2015 ($)
Exhibit 22: Cost comparison of key drugs per treatment 2015 ($)
Exhibit 23: Impact of challenges
Exhibit 24: Competitive structure analysis of global intravenous iron drugs market 2016
Exhibit 25: Market share analysis 2016
Exhibit 26: Competitive analysis of global intravenous iron drugs market
Exhibit 27: Strategic success factors of companies in global intravenous iron drugs market
Exhibit 28: Allergan: Strength assessment
Exhibit 29: Allergan: Strategy assessment
Exhibit 30: Allergan: Opportunity assessment
Exhibit 31: AMAG Pharmaceuticals: Key highlights
Exhibit 32: AMAG Pharmaceuticals: Strength assessment
Exhibit 33: AMAG Pharmaceuticals: Strategy assessment
Exhibit 34: AMAG Pharmaceuticals: Opportunity assessment
Exhibit 35: AMAG Pharmaceuticals: YoY revenue and growth rate of Feraheme ($ millions)
Exhibit 36: Daiichi Sankyo: Key highlights
Exhibit 37: Daiichi Sankyo: Strength assessment
Exhibit 38: Daiichi Sankyo: Strategy assessment
Exhibit 39: Daiichi Sankyo: Opportunity assessment
Exhibit 40: Daiichi Sankyo: YoY revenue and growth rate of Injectafer 2013-2015 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 42: Galenica: Key highlights
Exhibit 43: Galenica: Strength assessment
Exhibit 44: Galenica: Strategy assessment
Exhibit 45: Galenica: Opportunity assessment
Exhibit 46: Galenica: YoY revenue and growth rate of Ferinject 2013-2015 ($ millions)
Exhibit 47: Galenica: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 48: Pharmacosmos: Key highlights
Exhibit 49: Pharmacosmos: Strength assessment
Exhibit 50: Pharmacosmos: Strategy assessment
Exhibit 51: Pharmacosmos: Opportunity assessment